| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| thalidomide | protein cereblon | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
0.91 | approved,investigational,withdrawn | inhibitor |
| thalidomide | protein cereblon | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
0.91 | approved,investigational,withdrawn | inhibitor |
| thalidomide | fibroblast growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
0.11 | approved,investigational,withdrawn | antagonist |
| thalidomide | fibroblast growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
0.11 | approved,investigational,withdrawn | antagonist |
| thalidomide | nuclear factor nf-kappa-b p105 subunit | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
0.08 | approved,investigational,withdrawn | antagonist |
| thalidomide | nuclear factor nf-kappa-b p105 subunit | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
0.08 | approved,investigational,withdrawn | antagonist |
| thalidomide | alpha1-acid glycoprotein | small molecule | NA | drugbank | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
NA | approved,investigational,withdrawn | binder |
| thalidomide | alpha1-acid glycoprotein | small molecule | NA | drugbank | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
NA | approved,investigational,withdrawn | binder |
| thalidomide | alpha1-acid glycoprotein | small molecule | NA | drugbank | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
NA | approved,investigational,withdrawn | binder |
| thalidomide | alpha1-acid glycoprotein | small molecule | NA | drugbank | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
NA | approved,investigational,withdrawn | binder |
| thalidomide | prostaglandin g/h synthase 2 | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
0.14 | approved,investigational,withdrawn | antagonist |
| thalidomide | prostaglandin g/h synthase 2 | small molecule | NA | drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
0.14 | approved,investigational,withdrawn | antagonist |
| thalidomide | tumor necrosis factor | small molecule | Successful target | TTD , drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
0.27 | approved,investigational,withdrawn | inhibitor |
| thalidomide | tumor necrosis factor | small molecule | Successful target | TTD , drugbank , DGIDB | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
0.27 | approved,investigational,withdrawn | inhibitor |
| thalidomide | dna | small molecule | NA | drugbank | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] Coronavirus Infections[MeSHID:D018352] Disease[MeSHID:D004194] |
NA | approved,investigational,withdrawn | intercalation |
| thalidomide | dna | small molecule | NA | drugbank | Erythema Nodosum[MeSHID:D004893] Recurrence (disease attribute)[MeSHID:D012008] Erythema[MeSHID:D004890] Maintenance[MeSHID:D008283] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Multiple Myeloma[MeSHID:D009101] |
NA | approved,investigational,withdrawn | intercalation |
| click here to return to the previous page | ||||||||